Cancers that demonstrated decreased HER3 protein versus mRNA expression included kidney renal clear cell carcinoma, liver hepatocellular carcinoma and clear cell ovarian cancer, whereas those with increased HER3 protein expression included HER2+ breast cancer, bladder carcinoma and serous ovarian cancer. This evidence concerns the gene ERBB2 and ovarian serous adenocarcinoma.